Here's Why Quest Diagnostics (DGX) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
DGX - Quest Diagnostics Incorporated
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$250.00
DETAILS
HIGH:
$260.00
LOW:
$225.00
MEDIAN:
$255.00
CONSENSUS:
$250.00
UPSIDE:
8.24%
Stock News
Quest Diagnostics Incorporated $DGX Stock Holdings Lifted by Eastern Bank
Eastern Bank boosted its stake in Quest Diagnostics Incorporated (NYSE: DGX) by 9.3% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 207,720 shares of the medical research company's stock after acquiring an additional 17,751 shares during the quarter. Eastern Bank owned 0.19% of Quest
Dividend Champion, Contender, And Challenger Highlights: Week October 4
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
Haystack MRD® Demonstrates Robust Clinical Performance in Specimen Cohort from the Landmark DYNAMIC Colorectal Cancer Trials
Test showed 100% specificity, with no false-positive results in the cohort, at both 3- and 5-year follow-up, and sensitivity of 100% and 83.3%, respectively, for predicting disease recurrence SECAUCUS, N.J., Oct. 1, 2026 /PRNewswire/ -- A new study published in The Journal of Molecular Diagnostics showed that the Haystack MRD® test is highly accurate at detecting residual and recurrent disease, demonstrating clinical performance in specimens from the landmark DYNAMIC colorectal cancer trial series.
Quest Diagnostics Stock Gains 36.3% YTD: What's Behind the Rally?
DGX's 36.3% YTD rise reflects momentum in advanced diagnostics, channel growth, AI adoption and cost savings.
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Quest Diagnostics Incorporated: Testing Growth Keeps Me Bullish Despite Medicare Headwinds
Quest Diagnostics Incorporated's recurring testing demand provides a foundation for growth through hospital partnerships, dialysis services, and advanced diagnostics. Their dialysis testing and advanced diagnostics add growth opportunities, although their value ultimately depends on execution and reimbursement. So far, DGX's cash flows seem to be benefiting from the acquisition strategy, but if this falters, it may lead to write-downs of its sizable goodwill on the balance sheet.
Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026
SECAUCUS, N.J., Sept. 22, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its third quarter 2026 financial results on Thursday, October 22, 2026, before the market opens.
Why Quest Diagnostics Holdings Stock Dropped Today
Medicare and Medicaid have been overpaying Quest Diagnostics for years, says the government. Starting next year, they plan to cut reimbursement of lab testing by 15%.
Quest Diagnostics Study Finds High Tick-Borne Disease Co-Exposure
DGX study finds nearly one-third of Lyme-seropositive patients had antibodies to another tick-borne pathogen, highlighting broader testing needs.
Is This the Right Time to Add DGX Stock to Your Portfolio?
Quest Diagnostics gains momentum from customer wins, advanced diagnostics and AI initiatives, while reimbursement uncertainty, costs and debt pose challenges.
Quest Diagnostics Sees Growth Outpace Targets as Consumer Testing Surges
Quest Diagnostics (NYSE: DGX) CEO and President Jim Davis said the diagnostic testing company is exceeding the growth framework it outlined at its prior investor day, driven largely by organic growth, consumer-health demand and partnerships rather than a heavier-than-expected pace of acquisitions. Davis said Quest had previously targeted 4% to 5% revenue growth, including 1% to
Quest Diagnostics Sees Growth Outpace Targets as Consumer Testing Surges
Quest Diagnostics NYSE: DGX CEO and President Jim Davis said the diagnostic testing company is exceeding the growth framework it outlined at its prior investor day, driven largely by organic growth, consumer-health demand and partnerships rather than a heavier-than-expected pace of acquisitions.
Nearly 1 in 3 Patients with Suspected Lyme Disease are Co-Positive for Other Tick-Borne Pathogens, Finds Study by Quest Diagnostics
Study published in JAMA Network Open of over 193,000 patients nationwide reveals that individuals with evidence of exposure to Borrelia burgdorferi, the bacterium that causes Lyme disease, are more than four times as likely to have antibodies against other tick-borne pathogens compared to those without. SECAUCUS, N.J.
Corient Private Wealth LP Sells 5,233 Shares of Quest Diagnostics Incorporated $DGX
Corient Private Wealth LP decreased its position in Quest Diagnostics Incorporated (NYSE: DGX) by 13.3% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 34,092 shares of the medical research company's stock after selling 5,233 shares during the period. Corient Private Wealth
Fed Hikes Interest Rates, Signals Another: 4 Low-Beta Defensive Picks
Fed hikes rates and signals another, putting MGEE, ADM, DOLE and DGX in focus as low-beta defensive picks.
Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run?
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Nine in 10 Voters Express Concern That Medicare Lab Payment Cuts Will Harm Patient Access to Diagnostic Lab Testing, Finds National Survey from Quest Diagnostics
75% of registered voters surveyed call diagnostic testing "very important" to their care, and a bipartisan majority wants Congress to pass the RESULTS Act before additional Medicare cuts are scheduled to take effect January 2027 SECAUCUS, N.J., Sept. 16, 2026 /PRNewswire/ -- A new national survey finds the overwhelming majority of American voters rely on diagnostic laboratory testing to guide their healthcare decisions and are deeply concerned about scheduled Medicare payment cuts that could put that access at risk.
Quest Diagnostics (NYSE:DGX) Reaches New 52-Week High – Time to Buy?
Quest Diagnostics Incorporated (NYSE: DGX - Get Free Report)'s stock price hit a new 52-week high on Wednesday. The stock traded as high as $248.65 and last traded at $247.1970, with a volume of 1373537 shares. The stock had previously closed at $237.89. Analyst Ratings Changes A number of brokerages have recently issued reports on
Quest Diagnostics Incorporated (DGX) Presents at 2026 Global Healthcare Conference Transcript
Quest Diagnostics Incorporated (DGX) Presents at 2026 Global Healthcare Conference Transcript
Price Targets
Quest Diagnostics price target raised to $260 from $250 at Barclays
$260.00
(was $228.46)
Luke Sergott
·
Barclays
Quest Diagnostics price target raised to $260 from $250 at Truist
$260.00
(was $246.48)
Truist Financial
Quest Diagnostics price target raised to $245 from $232 at UBS
$245.00
(was $235.58)
UBS
Quest Diagnostics price target raised to $260 from $225 at Argus
$260.00
(was $235.34)
Argus Research
Quest Diagnostics price target raised to $232 from $220 at UBS
$232.00
(was $231.30)
Kevin Caliendo
·
UBS
Quest Diagnostics price target raised to $255 from $236 at Baird
$255.00
(was $227.90)
Robert W. Baird
Quest Diagnostics price target raised to $250 from $230 at Barclays
$250.00
(was $227.90)
Barclays
Quest Diagnostics price target raised to $245 from $225 at Jefferies
$245.00
(was $227.90)
Jefferies
Quest Diagnostics price target raised to $236 from $232 at Baird
$236.00
(was $207.44)
Robert W. Baird
Quest Diagnostics price target raised to $225 from $210 at Evercore ISI
$225.00
(was $205.18)
Evercore ISI
Quest Diagnostics price target raised to $225 from $220 at Jefferies
$225.00
(was $205.18)
Jefferies
Quest Diagnostics target cut, added to 'Tactical Outperform' list at Evercore
$210.00
(was $198.81)
Evercore ISI
Quest Diagnostics price target raised to $235 from $210 at Mizuho
$235.00
(was $209.32)
Mizuho Securities
Quest Diagnostics price target raised to $210 from $190 at UBS
$210.00
(was $206.72)
UBS
Quest Diagnostics price target raised to $220 from $205 at Truist
$220.00
(was $205.62)
Truist Financial
Quest Diagnostics price target raised to $220 from $190 at Evercore ISI
$220.00
(was $205.43)
Elizabeth Anderson
·
Evercore ISI
Quest Diagnostics price target raised to $219 from $203 at Baird
$219.00
(was $205.35)
Robert W. Baird
Quest Diagnostics price target raised to $220 from $215 at Jefferies
$220.00
(was $205.24)
Tycho Peterson
·
Jefferies
Quest Diagnostics upgraded to Overweight from Equal Weight at Barclays
$210.00
(was $182.35)
Barclays
Quest Diagnostics price target raised to $200 from $190 at Piper Sandler
$200.00
(was $182.18)
Piper Sandler